Last reviewed · How we verify
Adjunct brexpiprazole
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy.
Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy. Used for Adjunctive treatment of major depressive disorder in adults.
At a glance
| Generic name | Adjunct brexpiprazole |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Drug class | Serotonin-dopamine activity modulator (SDAM) |
| Target | Dopamine D2 receptor, Serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Brexpiprazole modulates dopaminergic and serotonergic neurotransmission through partial agonism at D2 and 5-HT1A receptors. When used adjunctively with antidepressants, it enhances therapeutic response in major depressive disorder by fine-tuning monoamine signaling. This mechanism differs from typical antipsychotics by providing activity modulation rather than receptor blockade.
Approved indications
- Adjunctive treatment of major depressive disorder in adults
Common side effects
- Akathisia
- Weight gain
- Restlessness
- Tremor
- Dizziness
Key clinical trials
- Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder (PHASE3)
- Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder (PHASE3)
- Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (PHASE3)
- Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment (PHASE3)
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment (PHASE3)
- Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD) (PHASE3)
- Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjunct brexpiprazole CI brief — competitive landscape report
- Adjunct brexpiprazole updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI